Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 10/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13394861 | 1.00 | CYP11B2 (0.43) | CYP11B2CYP11B1CHRNB2CHRNA4CHRNA3 | |
| SCHEMBL13394901 | 1.00 | CYP11B2 (0.43) | CYP11B2CYP11B1CHRNB2CHRNA4CHRNA3 | |
| SCHEMBL13394909 | 0.88 | BRAF (0.35) | CHRNA3 | |
| SCHEMBL3174246 | 0.88 | BRAF (0.35) | CHRNA3 | |
| SCHEMBL13394888 | 0.88 | BRAF (0.35) | CHRNA3 | |
| SCHEMBL13395064 | 0.86 | CYP11B2 (0.39) | CYP11B2CYP11B1CHRNB2CHRNA4CHRNA3 | |
| SCHEMBL3188918 | 0.86 | CYP11B2 (0.39) | CYP11B2CYP11B1CHRNB2CHRNA4CHRNA3 | |
| SCHEMBL5119729 | 0.85 | CYP11B2 (0.45) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL3178105 | 0.84 | CYP11B1 (0.39) | CYP11B2CYP11B1CYP17A1CYP19A1 | |
| SCHEMBL13395069 | 0.84 | CYP11B1 (0.39) | CYP11B2CYP11B1CYP17A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | COATS STEVEN J | 2010-04-15 | — | — | US | claimed |
| EP-1833826-B1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | claimed |
| US-7439239-B2 | Tricyclic δ- opioid modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-10-21 | — | — | US | claimed |
| EP-1833826-A2 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-19 | — | — | EP | claimed |
| WO-2006069276-A2 | TRICYCLIC ō-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | claimed |
| US-20060135763-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | claimed |
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | COATS STEVEN J | 2010-04-15 | — | — | US | disclosed |
| US-7652005-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-26 | — | — | US | disclosed |
| EP-1833826-B1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | disclosed |
| US-20090042871-A1 | Tricyclic Delta-Opioid Modulators | COATS STEVEN J | 2009-02-12 | — | — | US | disclosed |
| US-7439239-B2 | Tricyclic δ- opioid modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-10-21 | — | — | US | disclosed |
| EP-1833826-A2 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069276-A2 | TRICYCLIC ō-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135763-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | CYP11B2 415/4885CYP11B1 411/4885CHRNB2 119/4885 |
| US-20060135763-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | CYP11B2 416/4885CYP11B1 426/4885CHRNB2 116/4885 |
| US-20090042871-A1 | Tricyclic Delta-Opioid Modulators | OPRD1, OPRK1, OPRL1 | CYP11B2 416/4885CYP11B1 426/4885CHRNB2 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.